• Chemistry Analysis
  • Separation Center
  • Center of Natural Product
  • Impurity Isolation and Identification
  • Physicochemical Characterization & Others
  • Pharmaceutical Analysis
  • ASMS Screening
  • Biology
  • In vitro Biology
  • Enzymes/Biochemical Assays
  • Ion Channel
  • Cellular Assays
  • GPCR, Transporter and NHR
  • Radioactive Assays
  • Cancer Cell Panel & In Vitro Oncology Assays
  • In Vitro Assays for Diabetes and Other Metabolic Diseases
  • High Throughput Screening
  • High Content Platform
  • Protein Expression and Purification
  • In vivo Pharmacology & PK/PD
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Fibrosis: Lung, Liver, Kidney
  • Central Nervous System & Pain
  • Respiratory: Asthma & COPD
  • IBS/IBD Animal Models
  • Large Animal Disease Models
  • Infectious Disease
  • Antiviral Services
  • Virology Assays Supporting Human Clinical Trials
  • Antibacterial In Vitro Screening and Pharmacology Services
  • HBV Platform
  • Safety and Early Toxicity
  • In Vitro Safety Profiling for Medchem Support
  • In Vitro Tox Assays for Medchem Support
  • Early Stage Safety Assessment
  • Oncology & Immunology
  • CRISPR/Cas9 Gene Editing
  • In Vitro & In Vivo Library Screening
  • In Vivo CRISPR Animal Models and Services
  • Gene Therapy
  • Tumor Models
  • Cell Line-Derived Xenograft (CDX) Tumor Models
  • Patient-Derived Xenograft (PDX) Tumor Models
  • Syngeneic Tumor Models
  • Human Immune Checkpoint Gene KI Mouse Models
  • hPBMC/HSC Humanized Models
  • Immuno-oncology
  • Translational Oncology
  • Biomarker
  • Discovery Biomarker
  • Clinical Biomarker
  • Autoimmune and Inflammatory Animal Models
  • OncoWuXi Database
  • Structure Based Drug Discovery
  • Protein Production
  • X-ray Crystallography
  • CryoEM
  • Biophysical Assays and Screening
  • FBDD - Fragment Screening
  • Biopharmaceutical Assays
  • Crelux
  • HD Biosciences
  • About Us
  • About WuXi RSD
  • RSD Leadership
  • About WuXi AppTec
  • News & Events
  • News
  • Upcoming Events
  • Resource Library
  • Newsletters
  • Latest Sciences
  • Literature Download
  • Contact
  • CN
    Non-GLP safety and toxicity assessment for cadidate selection

    Overview

    Our Safety Pharmacology group profiles compounds for potential adverse drug reactions at various R&D stages, thereby helping to deliver high-quality drug candidates faster and at lower cost.

     

    Integrated Cardiovascular Safety Assessment

  • Cardiac ion channel safety panel with manual and automated patch-clamp: all CIPA recommended channels including hERG, hCav1.2, hNav1.5 (early and late), hKCNQ1/mink, hKv4.3/KChIP2.2, hKir2.1 channels
  • Human stem cell derived cardiomyocytes cardiotoxicity testing with MEA
  • Action potential recordings in heart muscle and/or Purkinje fibers
  • Telemetry ECG, blood pressure and core body temperature recordings in freely moving animals
  •  

    In Vivo CNS Safety Assessments

  • Irwin or FOB test
  • Rotarod test
  • Locomotors activity
  • Grip strength
  •  

    Off-Target Panel Screening

  • >90 Kinase Assay 
  • 100 GPCRs (For GPCR list, please click here)
  •  

    In Vitro Safety and Selectivity Profiling 

    Identify off-target based adverse drug reactions (ADR) at early stage of drug discovery. Such information may help guide compounds of interest through downstream in vivo tests for potential liabilities, and reduce attrition of drug candidates and even withdrawal of approved drugs.

    Led by a group of experienced scientists in drug discovery, safety panel team offers in vitro mini-Safety Panel Service for early pharmacological profiling of off-target and adverse effects of lead compounds or PCCs in drug development stage. Data are also useful for drug candidate SAR design. Assay targets in the panel are selected to form a minimal panel, recommended by scientists from four major pharmaceutical companies, to provide broad and diverse early in vitro safety assessments of testing compounds. Compounds can be screened by radioligand binding, biochemical and/or functional assays.

    (Learn More)

     

     

    Business Contact 

  • North America: Declan Ryan,  declan.ryan@wuxiapptec.com
  • Europe and Israel: Dave Madge,  dave_madge@wuxiapptec.com
  • China: Marcher Xu,  xu_longji@wuxiapptec.com
  • Japan: Yan Zhu,  yan_zhu@wuxiapptec.com
  • Korea: Suk Young Cho,  sycho@wuxiapptec.com